CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

Author： DiJoseph John   Dougher Maureen   Armellino Douglas   Kalyandrug Lyka   Kunz Arthur   Boghaert Erwin   Hamann Philip   Damle Nitin  

Publisher： Springer Publishing Company

ISSN： 0340-7004

Source： Cancer Immunology, Immunotherapy, Vol.56, Iss.7, 2007-07, pp. : 1107-1117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye   Polson Andrew  

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin’s lymphoma

By Schütt P.   Zimmermann K.   Derks C.   Ebeling P.   Welt A.   Poser M.   Hense J.   Metz K.   Anhuf J.   Sandmann M.   Neise M.   Moritz T.   Stuschke M.   Niederle N.   Seeber S.   Nowrousian Mohammad  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 459-466

Springer Publishing Company

Access to resources Recommend Favorite

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

By DiJoseph John   Dougher Maureen   Evans Deborah   Zhou Bin-Bing   Damle Nitin  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 741-749

Springer Publishing Company

Access to resources Recommend Favorite

Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma: single institution experience

By Wang Bufei   Huang Huiqiang   Bu Qing   Xia Zhongjun   Lin Xubin   Wang Fenghua   Li Yuhong   Peng Yulong   Pan Zhanhe   Wang Shusen   Lin Tongyu   Jiang Wenqi   Guan Zhongzhen  

The Chinese-German Journal of Clinical Oncology, Vol. 5, Iss. 6, 2006-12 ,pp. : 402-406

Springer Publishing Company

Access to resources Recommend Favorite

Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma

By Dzietczenia Justyna   Wróbel Tomasz   Mazur Grzegorz   Poręba Rafał   Jaźwiec Bożena   Kuliczkowski Kazimierz  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 743-746

Humana Press, Inc

Access to resources Recommend Favorite